Cited by CrossRef (6)
- Sudhir Kumar, Atul Sharma, Prabhat Singh Malik, Ajay Gogia, Neha Pathak, Ranjit Kumar Sahoo, Ritu Gupta, Chandra Prakash Prasad, Lalit Kumar. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. Br J Haematol 2022;198:288
- Darren Pan, Joshua Richter. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. CMAR 2023;Volume 15:741
- Scott R. Goldsmith, Mark A. Fiala, Brandon Wang, Mark A. Schroeder, Tanya M. Wildes, Armin Ghobadi, Keith Stockerl-Goldstein, Ravi Vij. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol 2020;99:1041
- Ji Hyun Lee, Sung-Hyun Kim. Treatment of relapsed and refractory multiple myeloma. Blood Res 2020;55:S43
- Seung-Shin Lee, Je-Jung Lee. Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma. Chonnam Med J 2019;55:25
- Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Joanna Drozd-Sokolowska, Edyta Subocz, Danuta Blonska, Malgorzata Razny, Agnieszka Druzd-Sitek, Jadwiga Holojda, Alina Swiderska, Lidia Usnarska-Zubkiewicz, Anna Masternak, Krzysztof Giannopoulos. Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. JCM 2021;10:5504